Teva Pharmaceuticals v. Sandoz: availability of generic glatiramer acetate and the impact to patent litigation claim construction.
نویسندگان
چکیده
In the upcoming case of Teva Pharmaceuticals v. Sandoz, the U.S. Supreme Court will address how much deference the appellate court should afford to a trial court's claim construction ruling. The effect of this decision will be far-reaching, as how claims are construed can determine whether a patent is infringed or not infringed, valid or invalid.
منابع مشابه
Glatiramer acetate therapy: the plot thickens.
G LATIRAMER ACETATE (COPAXONE; TEVA Pharmaceuticals, North Wales, Pa) is a random polymer of glutamic acid, lysine, alanine, and tyrosine, and is of considerable interest for its ability to reduce the frequency of relapses in relapsing-remitting multiple sclerosis (MS). Several mechanisms have been proposed to explain these findings. Lando et al suggested that inhibition of clinical disease in ...
متن کاملHow amending ANDA specifications can win or lose pharmaceutical patent litigation
Martin S. Masar III (L), an associate with Katten Muchin Rosenman in Chicago, has a variety of experience in patent litigation and prosecution, as well as in other areas of intellectual property and antitrust litigation. His practice focuses on chemistry, pharmaceutical arts, nanotechnology and biotechnology. Thomas J. Maas (R), an associate with the firm, concentrates his practice on resolving...
متن کاملComparing the Biological Impact of Glatiramer Acetate with the Biological Impact of a Generic
For decades, policies regarding generic medicines have sought to provide patients with economical access to safe and effective drugs, while encouraging the development of new therapies. This balance is becoming more challenging for physicians and regulators as biologics and non-biological complex drugs (NBCDs) such as glatiramer acetate demonstrate remarkable efficacy, because generics for thes...
متن کاملEquivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial.
IMPORTANCE The patents for the first approved treatments for relapsing-remitting multiple sclerosis are expiring, creating the opportunity to develop generic alternatives. OBJECTIVE To evaluate in the Glatiramer Acetate Clinical Trial to Assess Equivalence With Copaxone (GATE) study whether generic glatiramer acetate (hereafter generic drug) is equivalent to the originator brand glatiramer ac...
متن کاملAnaphylaxis to Glatiramer Acetate
Glatiramer acetate (Copaxone, Teva Pharma) and interferon beta are the two only disease-modifying therapies for multiple sclerosis. Glatiramer acetate is known for frequently simulating mild, anaphylactoid reactions while true, IgEmediated allergic reactions have been hardly reported so far. Herein, we report two females suffering from multiple sclerosis who experienced rapidly aggravating hype...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Expert opinion on therapeutic patents
دوره 25 1 شماره
صفحات -
تاریخ انتشار 2015